Brief: Heat Biologics Presents Additional Phase 2 Interim Data In Advanced NSCLC Patients
11/11/2019 18:45
Nov 11 (Reuters) - Heat Biologics Inc HTBX.O :
* HEAT BIOLOGICS INC. - HEAT BIOLOGICS PRESENTS ADDITIONAL
PHASE 2
INTERIM DATA IN ADVANCED NSCLC PATIENTS AT THE SITC 34TH ANNUAL
MEETING
* HEAT BIOLOGICS INC - COMBINATION OF HS-110 AND NIVOLUMAB
IS
WELL-TOLERATED AND WHEN COMPARED TO CPI MONOTHERAPY
* HEAT BIOLOGICS INC - NO INCREASE IN THE INCIDENCE OF
IMMUNE-RELATED ADVERSE EVENTS HAS BEEN OBSERVED FROM COMBINATION
OF HS-110 AND NIVOLUMAB
Source text for Eikon: urn:newsml:reuters.com:*:nNDL3y4h6G
Further company coverage: HTBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scorpius Holdings
See all newsBrief: Scorpius Holdings Inc Files For Non Timely 10-K With U.S. SEC
Brief: Scorpius Holdings Files For Offering Up To 29.4 Million Shares Of Common Stock
Brief: Scorpius Holdings Announces Collaboration With Celltheon Corporation
Brief: Scorpius Holdings - Implementation Of Strategic Cost-Saving Measures Expected To Save Over $2 Mln Annually
Brief: Scorpius Holdings Announces Partnership With U.S. Biotech Company